Condition: Breast Cancer · Sponsor: Karolinska University Hospital
The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main questions it aims to answer are: * is T-DXd more effective than standard preoperative treatment? * are there markers in the tumor or blood of patients with HER2-positive breast cancer that can help us predict response to treatment? Participants will be divided into two groups, where one group will be treated with three courses of T-DXd and the other group will be treated with three courses standard of care treatment. Thereafter, further treatment will be decided by the tumor's molecular subtype.
This description comes directly from the study's public registry record.
Mats Hellström, BSc · (0046)0812370000 · mats.hellstrom@regionstockholm.se
Always discuss trial participation with your own doctor first.
| Skåne University Hospital | Malmö, Sweden | Not Yet Recruiting |
| Örebro University Hospital | Örebro, Sweden | Not Yet Recruiting |
| Sankt Gorans Hospital | Stockholm, Sweden | Not Yet Recruiting |
| Stockholm Southern Hospital | Stockholm, Sweden | Not Yet Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
| Norrlands University Hospital | Umeå, Sweden | Not Yet Recruiting |
| Uppsala University Hospital | Uppsala, Sweden | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05900206